Scott Antonia

Center for Cancer Immunotherapy, Duke University School of Medicine, Durham, NC, USA, United States

Achilles Therapeutics (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)Amgen (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)AstraZeneca (Consultant/Advisory Board)Bristol-Myers Squibb (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)CBMG (Consultant/Advisory Board)Celsius (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)GlaxoSmithKline (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)Memgen (Consultant/Advisory Board)Merck (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)Novartis (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Rapt (Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support)Samyang Biopharma (Consultant/Advisory Board)Venn (Consultant/Advisory Board)

Presentation(s):

• Real-World Treatment Patterns Before and After Receiving PD-L1 Test Results in Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)

  Sunday, August 28, 2022
  2:15 PM – 2:30 PM CEST